3
B.; allemande, B.; Matagne, A.; Miche, P. WO 01/62726 A2.; h)
exploited to build pyrrolinone ring. The notable features of the
synthesis involved inexpensive starting materials, simple reaction
condition, use of nonhazardous reagents and product formation in
excellent yield. The present protocols can be scalable for the
brivaracetam synthesis and could be helpful to prepare a library
of pyrrolinone derivatives as well.
Kumar, P.; Sankareswaran, S.; Mannam, M.; Gaddam, V. R.;
Chiluukuru, S.; Chaubey, B.K. WO 2018/042393 A1 i) Celal, A.;
Maeterlinck, A. M.; Arnaud, S.; d'Alsemberg, C. WO
2007/065634 Al; j) Surtees, J.; Bouvy, D.; Thomas, A.; Combret,
Y.; Frank, M.; Schmidt, G.; Duchene, G. US 2008/0009638 A1.
(a) Chavan, S. P.; Pathak, A. B.; Pawar, K. Synthesis 2015, 47, A-
F; (b) Pei, T.; Wang, W.; Widenhoefer, R. A. J. Am. Chem. Soc.
2003, 125, 648.
8.
9.
4. Acknowledgments
Chavan, S. P.; Pathak, A. B.; Kalkote, U. R. Synlett 2007, 2635.
10. a) Chavan, S. P.; Pasupathy, K.; Venkatraman, M. S.; Kale, R. R.
Tetrahedron Lett. 2004, 45, 6879; (b) Chavan, S. P.; Praveen, C.
Tetrahedron Lett. 2005, 46, 1939;(c) Chavan, S. P.; Thakkar, M.;
Jogadand, G. F. J. Org. Chem. 2006, 71, 8986; (d) Chavan, S. P.;
Sharma, P. S.; Sivappa, R.; Kalkote, U. R. Tetrahedron Lett. 2006,
47, 9301; (e) Chavan, S. P.; Pathak, A. B.; Dhawane, A. N.;
Kalkote, U. R. Synth. Commun. 2007, 37, 1503; (f) Chavan, S. P.;
Dhawane, A. N.; Kalkote, U. R. Tetrahedron Lett. 2007, 48, 965;
(g) Chavan, S. P.; Pathak, A. B.; Pandey, A.; Kalkote, U. R. Synth.
Commun. 2007, 37, 3143; (h) Li, W.-R.; Lin, S. T.; Hsu, N.-M.;
Chern, M.-S. J. Org. Chem. 2002, 67, 4702; (i) Chavan, S. P.
Tejwani, R. B.; Ravindranathan, T. J. Org. Chem. 2001, 66, 6197;
(j) Chavan, S. P.; Ramakrishna, G.; Gonnade, R. G.; Bhadbhade,
M. M. Tetrahedron Lett. 2004, 45, 7307; (k) Chavan, S. P.;
Chittiboyina, A. G.; Ravindranathan, T.; Kamat, S. K.; Kalkote,
U. R. J. Org. Chem. 2005, 70, 1901. (l) Chavan, S. P.; Lasonkar,
P. B.; Chavan, P. N. Tetrahedron: Asymmetry 2013, 24, 1473. (m)
Chavan, S. P.; Chavan, P. N.; Gonnade, R. G. RSC Adv. 2014, 4,
62281; (n) Chavan, S. P.; Chavan, P. N.; Khairnar, L. B. RSC Adv.
2014, 4, 11417; (o) Chavan, S. P.; Pawar, K. P.; Garai, S. RSC
Adv. 2014, 4, 14468.
11. (a) Krapcho, A. P.; Weimaster, J. F.; Eldridge, J. M.; Jahngen, E.
G. E.; Lovey, A. J.; Stephens, W. P. Journal of Organic Chemistry
1978, 43, 138; (b) Krapcho, A. P. Tetrahedron Letters 1974, 15,
1091; (c) Krapcho, A. P. Tetrahedron Letters 1967, 8, 215.
12. Trnka, T. M.; Grubbs, R. H., Accounts of Chemical Research
2001, 34, 18.
13. Benohoud, M.; Erkkilä, A.; Pihko, P. M. Org. Synth. 2010, 87,
201.
14. Anderson, J. C.; Skerratt, S. J. Chem. Soc., Perkin Trans. 2002, 1,
2871.
S. A. K and P. N. C thank CSIR, New Delhi for research
fellowship. We thank Dr. U. R. Kalkote for useful discussion.
The authors thank CSIR, New Delhi for financial support as of
XII Five Year Plan program under title ORIGIN (CSC-0108) and
ACT (CSC-0301).
5.
References and notes
1.
a) Hauser, W. A. Overview: Epidemiology, Pathology, and
Genetics in Epilepsy: A Comprehensive Textbook Lippincott-
Raven Publishers: Philadelphia, 1997; pp 11; (b) Brodie, M. J.;
Shorvon, S. D.; Canger, R.; Halász, P.; Johannessen, S.;
Thompson, P.; Wieser, H. G.; Wolf, P. Commission on European
Affairs: appropriate standards of epilepsy care across Europe:
ILEA. Epilepsia 1997, 38, 1245-1250, (c) World Health
Organization.
Epilepsy:
key
facts.
April 2012); (d) Ngugi, A. K.; Kariuki, S. M.; Bottomley, C.;
Kleinschmidt, I.; Sander, J. W.; Newton, C. R. Incidence of
epilepsy: a systematic review and meta-analysis. Neurology 2011,
77, 1005-1012; (e) Leitlinien fur Diagnostik und Therapie in der
Neurologie. 4. Uberarbeitete Auflage. ISBN 978-3-13-132414-6.
Georg Thieme Verlag: Stuttgart, 2008, 654ff; (f) Kelso, A. R. C.;
Cock, H. R. Advances in epilepsy. Br. Med. Bull. 2004, 72, 135-
148.
2.
3.
Werhahn, K. J. Epilepsy in the elderly. Dtsch. Arztebl. Int. 2009,
106, 135-142.
(a) Dreyfuss, F. E. and France, C. J. Classification of Epileptic
Seizures and the Epilepsies and Drugs of Choice for their
Treatmentin Antiepileptic Drugs Pharmacology and Therapeutics:
Handbook of Experimental Pharmacology; Springer: Berlin, 1999;
pp 1; (b) Lynch, B. A.; Lambeng, N.; Nocka, K.; Kensel-Hammes,
P.; Bajjalieh, S. M.; Matagne, A.; Fuks, B. The synaptic vesicle
protein SV2A is the binding site forthe antiepileptic drug
levetiracetam. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 9861-9866.
Klitgaard, H. Levetiracetam: the preclinical profile of a new class
of antiepileptic drugs? Epilepsia 2001, 42 Suppl 4, 13.
Two efficient approaches for synthesis of
4.
5.
6.
brivaracetam are reported.
Klein, P.; Diaz, A.; Gasalla, T.; Whitesides, J. Clinical
Pharmacology: Advances and Applications 2018, 10, 1.
a) US Food and Drug Administration. Brivaracetam [prescribing
information]
2016.
Available
from:
The syntheses were accomplished from the
overview.process&ApplNo=205836. Accessed July 4, 2017. b)
Pollard, JR.; Kulig, K. Curr. Opin. Investig. Drugs 2008, 9, 101-
107.
known and Cost-effective starting materials.
7.
(a) Surtees, J.; Bouvy, D.; Thomas, A.; Combret, Y.; Frank, M.;
Schmidt, G.; Duchene, G. US 2012, 8,338,621 B2; US 6,784,1 97;
(b) John, S.; Francoise, L.; Ousmane, D. WO 2005/028435 A1; (c)
Peng, W., Pixu, L., Qiang, W., Yuanhua, L., WO 2016/191435 Al;
(d) Thierry, D.; Jean; S.; Didier, N. WO 2017/076738 Al; (e)
Kenda. B. M.; Matagne. A. C., Talaga, P. E.; Pasau, P. M.;
Differding, E.; Lallemand, B. I.; Frycia, A. M.; Moureau, F. G.;
Klitgaard, H. V.; Gillard, M. R.; Fuks, B.; Michel, P. J. Med.
Chem., 2004, 47, 530; (f) Schule, A.; Merschaert, A.;
Szczepaniak, C.; Marechal, C.; Carly, N.; O’Rourke, J.; Ates, C.
Org. Process Res. Dev. 2016, 20, 1566.; g) Differding, E.; Kenda,
Intramolecular Pd-catalyzed oxidative
cyclization and Ring-Closing metathesis
reaction were used to construct pyrolinone
skeleton.